Detailed Narrative
Strong Q1 FY27 Performance Driven by Oncology and Exports
Sakar Healthcare Limited reported robust financial results for Q1 FY27, with revenue from operations growing 38% year-on-year to INR7,297 lakhs. EBITDA increased by 67% to INR2,125 lakhs, leading to an improved EBITDA margin of 29%. Profit after tax saw a significant jump of 120% to INR1,028 lakhs, primarily driven by the strong momentum in the oncology division and expanding global footprint.
Expanding Oncology Product Portfolio and Market Access
The company has developed 55 oncology molecules, with 32 dossiers ready for global launch. During the quarter, Sakar executed over 65 oncology product contracts and shared 261 oncology dossiers globally, resulting in 16 marketing authorizations received. This expansion is broadening the company's commercialization opportunities and increasing visibility across regulated and emerging markets, with a target of 100+ dossier approvals in the next 2-3 years.
Strategic Focus on Technology Transfer and API Integration
Technology transfer projects are becoming a crucial part of the oncology business model, with 33 ongoing projects with leading pharmaceutical companies. Seven projects have already secured site variation approvals in the UK and EU. Additionally, the company is strengthening its economics through backward integration, with 21 oncology APIs developed in-house, including 16 supported by written confirmations and ongoing CEP applications, aiming for better supply chain control and competitiveness. Five more APIs are in the pipeline for CEP approval, targeting a total of seven in the next few quarters⏳.
Bavla Facility as Cornerstone for Export Growth with Headroom
The EU-GMP approved oncology facility at Bavla is central to the export strategy, capable of supporting revenues of INR800 crores to INR1,000 crores over the next 4-5 years without significant incremental capital expenditure. This substantial headroom for growth is expected to drive operating leverage and margin expansion as product registrations convert into commercial launches and export volumes scale up. The company does not anticipate needing further capex for the next 3-4 years.
Outlook on Oncology Revenue and Margin Expansion
Management projects the oncology business to reach INR800-1,000 crores in revenue within three to four years, and approximately INR280-300 crores by FY28. For FY27, oncology export revenue is targeted at INR60-70 crores, a significant increase from INR6.5 crores in Q1 FY27. EBITDA margins are expected to cross 30% by the end of FY27, with API backward integration potentially pushing margins for integrated products to 35% plus.
Non-Oncology Business and Domestic CMO Growth
The Changodar facility continues to support non-oncology operations, providing stability through CDMO services, injectables, oral solids, and branded formulations. The non-oncology business is expected to grow at a CAGR of 7-8% over the next two to three years. The domestic CMO business, which was INR35 crores in FY26, is targeted to double in FY27, driven by increased contributions from partners like Emcure, Glenmark, and Zydus.